Roche has joined the rush into the obesity treatment market by buying Carmot Therapeutics for $2.7bn upfront – and could have a muscle-building drug combination to help it compete.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?